Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Stimunity

Stimunity
2016 FOUNDED
PRIVATE STATUS
Seed LATEST DEAL TYPE
$2.47M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of stimulating drugs created to activate the innate immune system. The company's drugs utilizes endogenous STING activator encapsulated in a Virus-Like Particle to to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells, enabling physicians to treat patients that still do not respond to conventional immunotherapy in infectious disease and cancer.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 24, Rue du Faubourg Saint Jacques
  • 75014 Paris
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Stimunity’s full profile, request a free trial.

Stimunity Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 28-Feb-2018 $2.47M 00.000 Completed Pre-Clinical Trials
2. Grant 10-Jul-2017 00000 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Stimunity Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Portage Biotech Corporation Minority 000 0000 000000 0
Paris Bio-Tech Accelerator/Incubator Minority 000 0000 000000 0

Stimunity Executive Team (3)

Name Title Board
Seat
Contact
Info
Sylvain Carlioz Co-Founder & Chief Executive Officer
Nicolas Manel Ph.D Co-Founder & Scientific Advisor
Ian Walters MD Chairman of the Board

Stimunity Board Members (1)

Name Representing Role Since Contact
Info
Ian Walters MD Self Chairman of the Board 000 0000